Compile Data Set for Download or QSAR
Report error Found 297 Enz. Inhib. hit(s) with all data for entry = 2446
TargetProgrammed cell death 1 ligand 1(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM50239947(US9872852, Example 202 | CHEMBL4089730 | US2023030...)
Affinity DataIC50: 18nMAssay Description:All binding studies were performed in an HTRF assay buffer consisting of dPBS supplemented with 0.1% (withv) bovine serum albumin and 0.05% (v/v) Twe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/19/2019
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM365922(4-{[({2,6-dimethoxy-4- [(2-methyl-3-phenylphenyl) ...)
Affinity DataIC50: 22nMAssay Description:All binding studies were performed in an HTRF assay buffer consisting of dPBS supplemented with 0.1% (withv) bovine serum albumin and 0.05% (v/v) Twe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/19/2019
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM365862((3S)-4-{[(4-{[3-(2,3-dihydro-1,4- benzodioxin-6-yl...)
Affinity DataIC50: 43nMAssay Description:All binding studies were performed in an HTRF assay buffer consisting of dPBS supplemented with 0.1% (withv) bovine serum albumin and 0.05% (v/v) Twe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/19/2019
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM365904(2-(4-{[(2S)-2- (hydroxymethyl)pyrrolidin-1- yl]met...)
Affinity DataIC50: 53nMAssay Description:All binding studies were performed in an HTRF assay buffer consisting of dPBS supplemented with 0.1% (withv) bovine serum albumin and 0.05% (v/v) Twe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/19/2019
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM365902(2-{4-[(4-acetyl-1,4-diazepan-1- yl)methyl]-3,5- di...)
Affinity DataIC50: 53nMAssay Description:All binding studies were performed in an HTRF assay buffer consisting of dPBS supplemented with 0.1% (withv) bovine serum albumin and 0.05% (v/v) Twe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/19/2019
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM365901(2-[4-(azetidin-1-ylmethyl)-3,5- dimethoxyphenoxyme...)
Affinity DataIC50: 53nMAssay Description:All binding studies were performed in an HTRF assay buffer consisting of dPBS supplemented with 0.1% (withv) bovine serum albumin and 0.05% (v/v) Twe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/19/2019
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM365906(2-{4-[(3-hydroxypiperidin-1- yl)methyl]-3,5- dimet...)
Affinity DataIC50: 53nMAssay Description:All binding studies were performed in an HTRF assay buffer consisting of dPBS supplemented with 0.1% (withv) bovine serum albumin and 0.05% (v/v) Twe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/19/2019
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM365896(2-{3,5-dimethoxy-4-[(2- methylpyrrolidin-1- yl)met...)
Affinity DataIC50: 53nMAssay Description:All binding studies were performed in an HTRF assay buffer consisting of dPBS supplemented with 0.1% (withv) bovine serum albumin and 0.05% (v/v) Twe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/19/2019
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM365895(2-[3,5-dimethoxy-4-({[2- (pyridin-2-yl)ethyl]amino...)
Affinity DataIC50: 53nMAssay Description:All binding studies were performed in an HTRF assay buffer consisting of dPBS supplemented with 0.1% (withv) bovine serum albumin and 0.05% (v/v) Twe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/19/2019
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM365894(2-{3,5-dimethoxy-4- [(methylamino)methyl] phenoxym...)
Affinity DataIC50: 53nMAssay Description:All binding studies were performed in an HTRF assay buffer consisting of dPBS supplemented with 0.1% (withv) bovine serum albumin and 0.05% (v/v) Twe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/19/2019
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM365893(3-[({4-[(2-cyano-3- phenylphenyl)methoxy]-2,6- dim...)
Affinity DataIC50: 53nMAssay Description:All binding studies were performed in an HTRF assay buffer consisting of dPBS supplemented with 0.1% (withv) bovine serum albumin and 0.05% (v/v) Twe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/19/2019
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM365900(N-[(3S)-1-({4-[(2-cyano-3- phenylphenyl)methoxy]-2...)
Affinity DataIC50: 53nMAssay Description:All binding studies were performed in an HTRF assay buffer consisting of dPBS supplemented with 0.1% (withv) bovine serum albumin and 0.05% (v/v) Twe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/19/2019
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM365899(2-(4-{[3-(hydroxymethyl) piperidin-1-yl]methyl}-3,...)
Affinity DataIC50: 53nMAssay Description:All binding studies were performed in an HTRF assay buffer consisting of dPBS supplemented with 0.1% (withv) bovine serum albumin and 0.05% (v/v) Twe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/19/2019
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM365898(2-[3,5-dimethoxy-4-(pyrrolidin-1- ylmethyl)phenoxy...)
Affinity DataIC50: 53nMAssay Description:All binding studies were performed in an HTRF assay buffer consisting of dPBS supplemented with 0.1% (withv) bovine serum albumin and 0.05% (v/v) Twe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/19/2019
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM365897(2-{4-[(4-acetylpiperazin-1- yl)methyl]-3,5- dimeth...)
Affinity DataIC50: 53nMAssay Description:All binding studies were performed in an HTRF assay buffer consisting of dPBS supplemented with 0.1% (withv) bovine serum albumin and 0.05% (v/v) Twe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/19/2019
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM365921(({2,6-dimethoxy-4-[(2-methyl-3- phenylphenyl)metho...)
Affinity DataIC50: 53nMAssay Description:All binding studies were performed in an HTRF assay buffer consisting of dPBS supplemented with 0.1% (withv) bovine serum albumin and 0.05% (v/v) Twe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/19/2019
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM365912(2-(2-{2-[({2,6-dimethoxy-4-[(2- methyl-3-phenylphe...)
Affinity DataIC50: 53nMAssay Description:All binding studies were performed in an HTRF assay buffer consisting of dPBS supplemented with 0.1% (withv) bovine serum albumin and 0.05% (v/v) Twe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/19/2019
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM365909((2S)-1-({4-[(2-cyano-3- phenylphenyl)methoxy]-2,6-...)
Affinity DataIC50: 53nMAssay Description:All binding studies were performed in an HTRF assay buffer consisting of dPBS supplemented with 0.1% (withv) bovine serum albumin and 0.05% (v/v) Twe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/19/2019
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM365934((2S)-5-[({2,6-dimethoxy-4-[(2- methyl-3- phenylphe...)
Affinity DataIC50: 53nMAssay Description:All binding studies were performed in an HTRF assay buffer consisting of dPBS supplemented with 0.1% (withv) bovine serum albumin and 0.05% (v/v) Twe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/19/2019
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM365933(2-(2-{2-[({2,6-dimethoxy-4-[(2- methyl-3- phenylph...)
Affinity DataIC50: 53nMAssay Description:All binding studies were performed in an HTRF assay buffer consisting of dPBS supplemented with 0.1% (withv) bovine serum albumin and 0.05% (v/v) Twe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/19/2019
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM365926(4-[({2,6-dimethoxy-4-[(2-methyl- 3-phenylphenyl)me...)
Affinity DataIC50: 53nMAssay Description:All binding studies were performed in an HTRF assay buffer consisting of dPBS supplemented with 0.1% (withv) bovine serum albumin and 0.05% (v/v) Twe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/19/2019
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM365929(1-{2,6-dimethoxy-4-[(2-methyl- 3-phenylphenyl)meth...)
Affinity DataIC50: 53nMAssay Description:All binding studies were performed in an HTRF assay buffer consisting of dPBS supplemented with 0.1% (withv) bovine serum albumin and 0.05% (v/v) Twe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/19/2019
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM50091329(CHEMBL3582257 | US9872852, Example 196)
Affinity DataIC50: 53nMAssay Description:All binding studies were performed in an HTRF assay buffer consisting of dPBS supplemented with 0.1% (withv) bovine serum albumin and 0.05% (v/v) Twe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/19/2019
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM365946(N-{2-[({3-cyano-4-[(2-methyl-3-phenylphenyl)methox...)
Affinity DataIC50: 53nMAssay Description:All binding studies were performed in an HTRF assay buffer consisting of dPBS supplemented with 0.1% (withv) bovine serum albumin and 0.05% (v/v) Twe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/19/2019
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM365945((3S)-4-[({3-chloro-4-[(2- methyl-3- phenylphenyl)m...)
Affinity DataIC50: 53nMAssay Description:All binding studies were performed in an HTRF assay buffer consisting of dPBS supplemented with 0.1% (withv) bovine serum albumin and 0.05% (v/v) Twe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/19/2019
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM365968(2-[({6-[(2-methyl-3- phenylphenyl)methoxy]pyridin-...)
Affinity DataIC50: 53nMAssay Description:All binding studies were performed in an HTRF assay buffer consisting of dPBS supplemented with 0.1% (withv) bovine serum albumin and 0.05% (v/v) Twe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/19/2019
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM365984(1-[({2,6-dimethoxy-4-[(2- methyl-3- phenylphenyl)m...)
Affinity DataIC50: 53nMAssay Description:All binding studies were performed in an HTRF assay buffer consisting of dPBS supplemented with 0.1% (withv) bovine serum albumin and 0.05% (v/v) Twe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/19/2019
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM365982((2S,3S)-2-[({2,6-dimethoxy-4-[(2- methyl-3- phenyl...)
Affinity DataIC50: 53nMAssay Description:All binding studies were performed in an HTRF assay buffer consisting of dPBS supplemented with 0.1% (withv) bovine serum albumin and 0.05% (v/v) Twe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/19/2019
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM365981(2-[({2,6-dimethoxy-4-[(2-methyl- 3-phenylphenyl)me...)
Affinity DataIC50: 53nMAssay Description:All binding studies were performed in an HTRF assay buffer consisting of dPBS supplemented with 0.1% (withv) bovine serum albumin and 0.05% (v/v) Twe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/19/2019
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM365988((2S)-2-[({2,6-dimethoxy-4-[(2- methyl-3- phenylphe...)
Affinity DataIC50: 53nMAssay Description:All binding studies were performed in an HTRF assay buffer consisting of dPBS supplemented with 0.1% (withv) bovine serum albumin and 0.05% (v/v) Twe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/19/2019
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM365987(1-[({2,6-dimethoxy-4- [(2-methyl-3- phenylphenyl)m...)
Affinity DataIC50: 53nMAssay Description:All binding studies were performed in an HTRF assay buffer consisting of dPBS supplemented with 0.1% (withv) bovine serum albumin and 0.05% (v/v) Twe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/19/2019
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM365986(2-[({2,6-dimethoxy-4- [(2-methyl-3- phenylphenyl)m...)
Affinity DataIC50: 53nMAssay Description:All binding studies were performed in an HTRF assay buffer consisting of dPBS supplemented with 0.1% (withv) bovine serum albumin and 0.05% (v/v) Twe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/19/2019
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM365985({1-[({2,6-dimethoxy-4-[(2- methyl-3-phenylphenyl) ...)
Affinity DataIC50: 53nMAssay Description:All binding studies were performed in an HTRF assay buffer consisting of dPBS supplemented with 0.1% (withv) bovine serum albumin and 0.05% (v/v) Twe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/19/2019
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM365978(2-{[(4-{[3-(2H-1,3-benzodioxol-5- yl)-2-methylphen...)
Affinity DataIC50: 53nMAssay Description:All binding studies were performed in an HTRF assay buffer consisting of dPBS supplemented with 0.1% (withv) bovine serum albumin and 0.05% (v/v) Twe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/19/2019
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM366000((2R)-2-[({2,6-dimethoxy-4-[(2- methyl-3- phenylphe...)
Affinity DataIC50: 53nMAssay Description:All binding studies were performed in an HTRF assay buffer consisting of dPBS supplemented with 0.1% (withv) bovine serum albumin and 0.05% (v/v) Twe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/19/2019
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM365999((2R)-3-[({2,6-dimethoxy-4-[(2- methyl-3- phenylphe...)
Affinity DataIC50: 53nMAssay Description:All binding studies were performed in an HTRF assay buffer consisting of dPBS supplemented with 0.1% (withv) bovine serum albumin and 0.05% (v/v) Twe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/19/2019
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM365998(3-[({2,6-dimethoxy-4- [(2-methyl-3- phenylphenyl)m...)
Affinity DataIC50: 53nMAssay Description:All binding studies were performed in an HTRF assay buffer consisting of dPBS supplemented with 0.1% (withv) bovine serum albumin and 0.05% (v/v) Twe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/19/2019
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM365997((2S)-2-[({2,6-dimethoxy-4-[(2- methyl-3- phenylphe...)
Affinity DataIC50: 53nMAssay Description:All binding studies were performed in an HTRF assay buffer consisting of dPBS supplemented with 0.1% (withv) bovine serum albumin and 0.05% (v/v) Twe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/19/2019
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM366004((3R,4S)-4-[({2,6-dimethoxy-4- [(2-methyl-3- phenyl...)
Affinity DataIC50: 53nMAssay Description:All binding studies were performed in an HTRF assay buffer consisting of dPBS supplemented with 0.1% (withv) bovine serum albumin and 0.05% (v/v) Twe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/19/2019
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM366003((1S,2R)-2-[({2,6-dimethoxy-4- [(2-methyl-3- phenyl...)
Affinity DataIC50: 53nMAssay Description:All binding studies were performed in an HTRF assay buffer consisting of dPBS supplemented with 0.1% (withv) bovine serum albumin and 0.05% (v/v) Twe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/19/2019
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM366002(2-[({2,6-dimethoxy-4- [(2-methyl-3- phenylphenyl)m...)
Affinity DataIC50: 53nMAssay Description:All binding studies were performed in an HTRF assay buffer consisting of dPBS supplemented with 0.1% (withv) bovine serum albumin and 0.05% (v/v) Twe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/19/2019
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM366001((2S)-1-[({2,6-dimethoxy-4-[(2- methyl-3- phenylphe...)
Affinity DataIC50: 53nMAssay Description:All binding studies were performed in an HTRF assay buffer consisting of dPBS supplemented with 0.1% (withv) bovine serum albumin and 0.05% (v/v) Twe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/19/2019
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM365992((2S)-2-[({2,6-dimethoxy-4-[(2- methyl-3- phenylphe...)
Affinity DataIC50: 53nMAssay Description:All binding studies were performed in an HTRF assay buffer consisting of dPBS supplemented with 0.1% (withv) bovine serum albumin and 0.05% (v/v) Twe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/19/2019
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM365991((2R)2-[({2,6-dimethoxy-4-[(2- methyl-3- phenylphen...)
Affinity DataIC50: 53nMAssay Description:All binding studies were performed in an HTRF assay buffer consisting of dPBS supplemented with 0.1% (withv) bovine serum albumin and 0.05% (v/v) Twe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/19/2019
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM365990((2S)-2-[({2,6-dimethoxy-4-[(2- methyl-3- phenylphe...)
Affinity DataIC50: 53nMAssay Description:All binding studies were performed in an HTRF assay buffer consisting of dPBS supplemented with 0.1% (withv) bovine serum albumin and 0.05% (v/v) Twe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/19/2019
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM50239944(US9872852, Example 241 | CHEMBL4061613)
Affinity DataIC50: 53nMAssay Description:All binding studies were performed in an HTRF assay buffer consisting of dPBS supplemented with 0.1% (withv) bovine serum albumin and 0.05% (v/v) Twe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/19/2019
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM365996(1-[({2,6-dimethoxy-4- [(2-methyl-3- phenylphenyl)m...)
Affinity DataIC50: 53nMAssay Description:All binding studies were performed in an HTRF assay buffer consisting of dPBS supplemented with 0.1% (withv) bovine serum albumin and 0.05% (v/v) Twe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/19/2019
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM365995((2R)-2-[({2,6-dimethoxy-4-[(2- methyl-3- phenylphe...)
Affinity DataIC50: 53nMAssay Description:All binding studies were performed in an HTRF assay buffer consisting of dPBS supplemented with 0.1% (withv) bovine serum albumin and 0.05% (v/v) Twe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/19/2019
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM365994((2S)-3-[({2,6-dimethoxy-4-[(2- methyl-3- phenylphe...)
Affinity DataIC50: 53nMAssay Description:All binding studies were performed in an HTRF assay buffer consisting of dPBS supplemented with 0.1% (withv) bovine serum albumin and 0.05% (v/v) Twe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/19/2019
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM366016(2-[({2,6-dimethoxy-4- [(2-methyl-3- phenylphenyl)m...)
Affinity DataIC50: 53nMAssay Description:All binding studies were performed in an HTRF assay buffer consisting of dPBS supplemented with 0.1% (withv) bovine serum albumin and 0.05% (v/v) Twe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/19/2019
Entry Details
US Patent

Displayed 1 to 50 (of 297 total ) | Next | Last >>
Jump to: